← Upcoming Courses
Early Treatment Intensification in Type 2 Diabetes Mellitus (T2DM): Closing the Gap Before It Widens
Type 2 Diabetes Mellitus (T2DM) remains one of the leading chronic diseases globally, with many patients unable to achieve recommended glycemic targets despite the availability of effective treatment options. Traditional stepwise approaches to treatment intensification may contribute to prolonged periods of uncontrolled hyperglycemia, increasing the risk of diabetes-related complications.
This speaker-led educational meeting will explore the evolving treatment landscape in T2DM, with particular emphasis on the importance of early and timely treatment intensification. The session will examine the challenges associated with therapeutic inertia, the limitations of metformin monotherapy, and the growing evidence supporting the use of early combination therapy.
Participants will review key findings from the landmark VERIFY study and explore the emerging role of DPP-4 inhibitors in contemporary diabetes management. Through evidence-based presentations and practical case discussions, healthcare professionals will gain insights into individualizing treatment decisions and selecting appropriate therapeutic combinations based on different patient profiles. The meeting aims to strengthen clinical decision-making and support improved long-term outcomes for people living with T2DM.
The programme combines concise talks, case-based application, a high-level discussion, and extended Q&A sessions.
TOPICS TO BE PRESENTED
- The Changing T2DM Treatment Paradigm
- Therapeutic Inertia in T2DM
- Limitations of Metformin Monotherapy
- VERIFY Study: Evidence Supporting Early Combination Therapy
- Rationale for Early Treatment Combination
- The Evolving Role of DPP-4 Inhibitors in T2DM
- Choosing the Right Combination for the Right Patient
- Interactive Clinical Case Discussions
WHY YOU SHOULD ATTEND
· Stay Updated on Evolving T2DM Treatment Approaches
· Understand and Address Therapeutic Inertia
· Explore Evidence for Early Combination Therapy
· Learn How to Individualize Treatment Choices
· Apply Knowledge through Interactive Case Discussions
PROUDLY SPONSORED BY
This is a virtual event scheduled for Tuesday the 8th of September, 2026 at 16:00 GMT.
Target Audience: Doctors and Pharmacists
Date: Tuesday, 8th September, 2026
Time: 16:00 GMT (4:00 PM Local Time)
Moderator:
Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact in CRM!
PARTICIPANT CONSENT AND DATA PRIVACY NOTICE
By registering for the “Early Treatment Intensification in Type 2 Diabetes Mellitus (T2DM): Closing the Gap Before It Widens”, you consent to participate in this training hosted by Continuous Education Services (CES) on behalf of Novartis. Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC) & Pharmacy Council (PC). CES is committed to safeguarding your personal information and will not share any personal data with Novartis. Your data will only be shared with the relevant regulatory bodies, such as MDC & PC, solely for accrediting CPD points earned through this training. Participants are free to opt out of the meeting at any time; no further action is required on your part. Your privacy is respected, and your participation will be treated with the highest level of confidentiality.
Overview
Course Description
Type 2 Diabetes Mellitus (T2DM) remains one of the leading chronic diseases globally, with many patients failing to achieve glycemic targets despite the availability of effective therapies. Traditional management strategies have often relied on a stepwise treatment intensification approach, resulting in prolonged periods of uncontrolled hyperglycemia and increased risk of diabetes-related complications.
Through evidence-based presentations and practical case discussions, healthcare professionals will learn how to individualize treatment choices and select the most appropriate therapeutic combinations for different patient profiles. The meeting is designed to improve clinical decision-making and support better long-term outcomes for people living with T2DM.
What you will learn
At the end of this training, participants will be able to:
1. Understand the shift from traditional stepwise management to early treatment intensification in T2DM.
2. Recognize the causes and clinical consequences of therapeutic inertia.
3. Discuss the limitations of metformin monotherapy in maintaining durable
4. Review clinical evidence supporting early combination therapy, including findings from the VERIFY study.
5. Explain the rationale and benefits of initiating combination treatment earlier in the disease course.
6. Describe the role of DPP-4 inhibitors within contemporary T2DM treatment algorithms.
7. Apply patient-centered approaches in selecting appropriate therapeutic combinations.
8. Utilize clinical evidence to optimize treatment outcomes through practical case-based decision making.
Course Content
Lecture Sessions
- LIVE EVENT: Tuesday 8th September, 2026 @ 16:00 GMT (4:00 pm) 2 hours
Downloadables
No downloadable content added to this course yet.
About Facilitator
- 6 Courses on CES
Dr. Ebenezer Nii Ashalley Nikoi
BSc, MBChB, MSc, MGCP, FWACP
Senior Physician Specialist and Endocrinologist
Korle-Bu Teaching Hospital, Accra, Ghana.
Dr. Ebenezer Nii Ashalley Nikoi is a self-motivated and goal-oriented senior physician specialist and endocrinologist, recognized for his excellent communication, interpersonal, and problem-solving skills.
View full profile / courses
